ATE136219T1 - Kontrazeptionsverfahren und schema - Google Patents

Kontrazeptionsverfahren und schema

Info

Publication number
ATE136219T1
ATE136219T1 AT91203282T AT91203282T ATE136219T1 AT E136219 T1 ATE136219 T1 AT E136219T1 AT 91203282 T AT91203282 T AT 91203282T AT 91203282 T AT91203282 T AT 91203282T AT E136219 T1 ATE136219 T1 AT E136219T1
Authority
AT
Austria
Prior art keywords
progestogen
dosage units
equivalent
contraceptive
dosage
Prior art date
Application number
AT91203282T
Other languages
English (en)
Inventor
Bennink Herman Jan Ti Coelingh
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE136219(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE136219T1 publication Critical patent/ATE136219T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
  • Treatment Of Sludge (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seeds, Soups, And Other Foods (AREA)
  • Medicinal Preparation (AREA)
AT91203282T 1990-12-17 1991-12-12 Kontrazeptionsverfahren und schema ATE136219T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203372 1990-12-17

Publications (1)

Publication Number Publication Date
ATE136219T1 true ATE136219T1 (de) 1996-04-15

Family

ID=8205204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91203282T ATE136219T1 (de) 1990-12-17 1991-12-12 Kontrazeptionsverfahren und schema

Country Status (18)

Country Link
US (1) US5418228A (de)
EP (1) EP0491438B1 (de)
JP (1) JPH04290830A (de)
KR (1) KR100186780B1 (de)
CN (1) CN1036833C (de)
AT (1) ATE136219T1 (de)
AU (1) AU645637B2 (de)
CA (1) CA2057747C (de)
DE (1) DE69118494T2 (de)
DK (1) DK0491438T3 (de)
ES (1) ES2087965T3 (de)
FI (1) FI98985C (de)
GR (1) GR3020181T3 (de)
IE (1) IE62665B1 (de)
NO (1) NO179311C (de)
NZ (1) NZ240970A (de)
PT (1) PT99819B (de)
ZA (1) ZA919770B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5916593A (en) * 1994-09-22 1999-06-29 Akzo Nobel, N.V. Process of making dosage units by wet granulation
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
AU2926897A (en) * 1996-05-08 1997-11-26 American Home Products Corporation Oral contraceptive
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
AU3888697A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Progestin/estrogen oral contraceptive
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
SI0917466T1 (en) * 1996-07-26 2005-02-28 Wyeth Oral contraceptive
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
JP2004140323A (ja) * 2002-08-20 2004-05-13 Sharp Corp 半導体レーザ装置およびその製造方法
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
WO2004091535A2 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
EP1844765B1 (de) * 2003-06-13 2015-01-21 Skendi Finance, Ltd. Langsam freisetzende estradiol-progesterone formulierung
NZ545969A (en) * 2003-10-01 2008-07-31 Janssen Pharmaceutica Nv Extended triphasic contraceptive regimens
WO2005035717A2 (en) * 2003-10-03 2005-04-21 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
EP2343964A4 (de) 2008-10-08 2012-11-07 Agile Therapeutics Inc Transdermale freisetzung
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010042607A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc Transdermal delivery
CA2756222A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
EP2421545B1 (de) 2009-04-23 2017-12-06 JBS United Animal Health II LLC Verfahren und vorrichtung zur synchronisierung der befruchtungszeit
CN113398243A (zh) 2012-11-28 2021-09-17 联合动物健康第二有限责任公司 用于同步小母猪的授精时间的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4962098A (en) * 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women

Also Published As

Publication number Publication date
JPH04290830A (ja) 1992-10-15
ES2087965T3 (es) 1996-08-01
NZ240970A (en) 1994-05-26
AU645637B2 (en) 1994-01-20
PT99819A (pt) 1992-12-31
ZA919770B (en) 1992-09-30
NO914969L (no) 1992-06-18
KR100186780B1 (ko) 1999-05-01
IE62665B1 (en) 1995-02-22
NO179311B (no) 1996-06-10
CA2057747A1 (en) 1992-06-18
FI98985C (fi) 1997-09-25
EP0491438B1 (de) 1996-04-03
PT99819B (pt) 2001-05-31
FI915914A (fi) 1992-06-18
CN1036833C (zh) 1997-12-31
IE914272A1 (en) 1992-06-17
CA2057747C (en) 2003-07-29
EP0491438A1 (de) 1992-06-24
DE69118494T2 (de) 1996-08-22
GR3020181T3 (en) 1996-09-30
DK0491438T3 (da) 1996-07-08
FI915914A0 (fi) 1991-12-16
DE69118494D1 (de) 1996-05-09
NO914969D0 (no) 1991-12-16
AU8967991A (en) 1992-06-18
KR920011515A (ko) 1992-07-24
US5418228A (en) 1995-05-23
CN1062464A (zh) 1992-07-08
NO179311C (no) 1996-09-18
FI98985B (fi) 1997-06-13

Similar Documents

Publication Publication Date Title
ATE136219T1 (de) Kontrazeptionsverfahren und schema
ES2087964T3 (es) Contraceptivos orales bajos en estrogenos.
CY1105276T1 (el) Τριφασικο στοματικο αντισυλληπτικο
BR9710566A (pt) M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
NZ333862A (en) Triphasic oral contraceptive method and kit comprising a combination of progestin and estrogen
ATE249222T1 (de) Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee